HCA — HCA Healthcare, Inc.

HCA Healthcare Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Increased by 4.3% year-over-year.
• Adjusted EBITDA: Rose by nearly 2%, with an adjusted EBITDA margin decreasing by 50 basis points compared to the prior year.
• Diluted Earnings Per Share (EPS): Increased approximately 11% year-over-year.
• Volume Metrics:
  • Admissions: Up 0.9%
  • Equivalent Admissions: Up 1.3%
  • Inpatient Surgeries: Down 0.3%
  • Outpatient Surgeries: Down 1.7%
  • Emergency Room Visits: Up 0.3%
• Cash Flow from Operations: $2 billion, a 22% increase from the prior year.
• Capital Expenditures: Totaled $1.1 billion; share repurchases amounted to $1.57 billion, with $183 million paid in dividends.

2. Strategic Updates and Business Highlights

• Resiliency Plan: Continued focus on cost savings and network execution, with positive results from digital transformation and AI initiatives.
• Network Expansion: Increased overall sites of care by over 4%, added nearly 1% in hospital beds, and expanded emergency room capacity by 4%.
• Medicaid Supplemental Payments: Net benefits exceeded expectations, contributing an additional $200 million to adjusted EBITDA.
• Quality Improvements: Enhanced patient satisfaction and quality measures, alongside reduced average length of stay.

3. Forward Guidance and Outlook

• Volume Growth: Management maintains a full-year volume growth assumption of 2% to 3%, despite a lower-than-expected performance in Q1.
• Adjusted EBITDA Guidance: Full-year guidance remains unchanged, with expectations of $600 million to $900 million impact from exchanges.
• Payer Mix: Management anticipates continued fluidity in payer mix due to changes in health insurance exchanges.
• Capital Projects: A pipeline of $5.5 billion to $6 billion in approved projects expected to contribute to growth over the next 24 to 30 months.

4. Bad News, Challenges, or Points of Concern

• Volume Shortfalls: Significant declines in respiratory-related admissions (down 42%) and emergency room visits (down 32%) due to a milder respiratory season and adverse weather conditions.
• Impact of Winter Storm: Estimated to have negatively affected adjusted EBITDA by approximately $180 million.
• Exchange Environment: A 15% decline in exchange equivalent adjusted admissions, with an increase in uninsured equivalent admissions by 16%, indicating a shift in patient demographics.
• Denials and Underpayments: Increased activity levels with payers regarding denials and underpayments, particularly in Medicare Advantage, remain a concern.

5. Notable Q&A Insights

• Internal Expectations: Results were slightly below internal expectations primarily due to volume shortfalls from respiratory conditions and winter storms.
• Medicaid Conversion Slowdown: Noted as a new trend, potentially influenced by external factors affecting patient willingness to fill out applications.
• Contracting for 2027: Management is about one-third through contracting for 2027 and remains optimistic about achieving favorable terms.
• AI Initiatives: Progress in AI applications is expected to enhance operational efficiency and patient care, with ongoing implementations across various facilities.
• Market Dynamics: Management expressed confidence in recovering volumes in the latter part of the year, aligning with original guidance despite Q1 setbacks.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and challenges faced by HCA Healthcare in Q1 2026, providing a balanced view of the company's performance and outlook.